Global Next Generation Sequencing Market 2015-2019
Next generation sequencing (NGS) technology is used to sequence millions of small fragments of DNA simultaneously. The technology is similar to capillary electrophoresis where the bases of small fragments of DNA are sequentially identified from signals emitted, and each fragment is resynthesized from a DNA template strand. The major difference is that NGS process is extended across millions of reactions in a massively parallel fashion, rather than restricted to a single or a few DNA fragments. This technology enables rapid sequencing of large stretches of DNA base pairs spanning entire genomes with highly sophisticated instruments capable of producing hundreds of gigabytes of data in a single sequencing run. NGS finds application in whole genome, exome, and transcriptome sequencing that provide a high-resolution and global view of various applications such as the cancer genome. NGS coupled with bioinformatics tools has revolutionized cancer research, diagnosis, and therapy. This technology helps to track and trace the spread of disease and foreign contaminants in drugs.
Technavio's analysts forecast the global next generation sequencing market to grow at a CAGR of 21.36% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global next generation sequencing market for the period 2015-2019. The global next generation sequencing market is divided into two segments: equipment, and reagents and consumables. To calculate the market size, the report considers the revenue generated from the sales of equipment, and reagents and consumables used in next generation sequencing in the following customer segments:
Technavio Announces the Publication of its Research Report – Global Next Generation Sequencing Market 2015-2019
Technavio recognizes the following companies as the key players in Global Next Generation Sequencing Market 2015-2019: Illumina, Roche Diagnostics and Thermo Fischer Scientific
Other Prominent Vendors in the market are: 10X Genomic, 23andMe, Ambry Genetics, Axeq Technologies, Beijing Genomics Institute, CLC bio, Clontech Laboratories, Fluidigm, Foundation Medicine, GATC Biotech, GeneDx, GENEWIZ, Gnomegen, Good Start Genetics, Ingenuity Systems, Knome, NABsys, Oxford Nanopore Technologies, Pathogenica, PerkinElmer, RainDance Technologies, Rubicon Genomics, Sequenom, Sigma-Aldrich, Source Biosciences and Takara Bio
Commenting on the report, an analyst from Technavio’s team said: “One of the major trend in this market is strategic alliances between large corporations and specialized companies for enhancing their business in genomic sequencing. For instance, in 2014 Thermo Fisher Scientific collaborated with Pfizer and GSK to develop oncology companion diagnostics using NGS technology. These alliances enhance the expertise in DNA sequencing and accelerate drug discovery efforts.”
According to the report, one of the major factors expected to drive the market is advances in applications of NGS in molecular biology and biomedical engineering. The evolution of NGS technology as a molecular microscope has created interest among researchers, hospitals, and pharmaceutical and life sciences companies in finding solutions for complex biological questions.
Further, the report states that one of the challenge is the lack of standardization in data analysis.
Illumina, Roche Diagnostics, Thermo Fischer Scientific, 10X Genomic, 23andMe, Ambry Genetics, Axeq Technologies, Beijing Genomics Institute, CLC bio, Clontech Laboratories, Fluidigm, Foundation Medicine, GATC Biotech, GeneDx, GENEWIZ, Gnomegen, Good Start Genetics, Ingenuity Systems, Knome, NABsys, Oxford Nanopore Technologies, Pathogenica, PerkinElmer, RainDance Technologies, Rubicon Genomics, Sequenom, Sigma-Aldrich, Source Biosciences, Takara Bio